The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA. Hims & Hers Health recently prepared for potential U.S. regulatory changes on peptide compounding by acquiring a California peptide facility and beginning ingredient testing, while also expanding. Peptides+ launches by November’s end, offering personalized treatments, blood testing, and ongoing clinical care.